Ποια είναι η τιμή για Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Η τιμή για Mabwell (Shanghai) Bioscience Co., Ltd. (688062) είναι $4.28

Ποια είναι η κεφαλαιοποίηση αγοράς για Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Η κεφαλαιοποίηση αγοράς για Mabwell (Shanghai) Bioscience Co., Ltd. (688062) είναι $1.71B

Mabwell (Shanghai) Bioscience Co., Ltd. (688062) Ιστορικό Τιμών

Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.

Έτος	Απόδοση
2026 (TTM)	-4.93%
2025	84.63%
2024	-29.85%
2023	101.02%
2022	0.00%

Έτος

Απόδοση

2026 (TTM)

-4.93%

2025

84.63%

2024

-29.85%

2023

101.02%

2022

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$548.36	39.87%	US
Argenx SE ARGX.US	$1.06K	50.29%	NL
CSL Limited CSL.AX	$121.53	-12.48%	AU
Moderna, Inc. MRNA.US	$140.81	475.44%	US
Lonza Group AG LONN.SW	$767.59	8.07%	CH

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα